NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs

Biochemical Pharmacology

Volumn 72, Issue 3, 2006, Pages 366-376

  Celli, Claudia M ^a   Tran, Namphuong ^a   Knox, Richard ^b   Jaiswal, Anil K ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b BIOCOMPATIBLES UK LTD   (United Kingdom)

Author keywords

Anti tumor drugs; Cytotoxicity; Metabolic activation; Mitomycin C; NRH:quinone oxidoreductase 2; Quinones

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; 7 N [2 (4 NITROPHENYLDITHIO)ETHYL]MITOMYCIN C; ANTINEOPLASTIC AGENT; BP 3,6 QUINONE; COMPLEMENTARY DNA; DIMETHYLBENZ[A]ANTHRACENE; MENADIONE; MITOMYCIN C; NRH QUINONE OXIDOREDUCTASE 2; OXIDOREDUCTASE; QUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIUM; CATALYSIS; CHO CELL; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DNA CROSS LINKING; DRUG ACTIVATION; DRUG DETOXIFICATION; DRUG METABOLISM; KERATINOCYTE; METABOLIC ACTIVATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; SKIN TUMOR; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BENZOPYRENES; BIOTRANSFORMATION; CELL SURVIVAL; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; CROSS-LINKING REAGENTS; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROQUINONES; INDOLEQUINONES; KERATINOCYTES; MICE; MICE, KNOCKOUT; MITOMYCIN; MITOMYCINS; QUINONE REDUCTASES; QUINONES; TRANSFECTION; VITAMIN K 3;

EID: 33745672949     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.04.029     Document Type: Article

References (41)

1. Venugopal R., Joseph P., and Jaiswal A.K. Gene expression of DT-diaphorase in cancer cells. In: Henry J.F., and Enrique C. (Eds). Oxidative stress and signal transduction (1997), Chapman & Hall, New York (NY) 441-475
2. Talalay P., Fahey J.W., Holtzclaw W.D., Prestera T., and Zhang Y. Chemoprotection against cancer by phase 2 enzyme induction. Toxicol Lett 82-83 (1995) 173-179
3. Riley R.J., and Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharm 43 (1992) 1657-1669
4. Long II D.J., and Jaiswal A.K. Mouse NRH:quinone oxidoreductase (NQO2): cloning of cDNA and gene- and tissue-specific expression. Gene 252 (2000) 107-117
5. Chesis P.L., Levin D.E., Smith M.T., Ernster L., and Ames B.N. Mutagenicity of quinones: pathways of metabolic activation and detoxification. Proc Natl Acad Sci USA 81 (1984) 1696-1700
6. Brunmark A., Cadenas E., Segura-Aguilar J., Lind C., and Ernster L. DT-diaphorase catalyzed two-electron reduction of various p-benzoquinone- and 1,4-naphthoquinone epoxides. Free Radic Biol Med 5 (1988) 133-143
7. Joseph P., and Jaiswal A.K. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) specifically prevents the formation of benzo(a)pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci USA 91 (1994) 8413-8417
8. Lind C., Hochstein P., and Ernster L. DT-diaphorase. Properties, reaction mechanism, metabolic function. A progress report. In: King T.E., Mason H.S., and Morrison M. (Eds). Oxidases and related redox systems (1982), Pergamon, Oxford 321-347
9. De Flora A. Prominent role of DT-diaphorase as a cellular mechanism reducing chromium (VI) and reverting its mutagenicity. Cancer Res 45 (1985) 3188-3196
10. Joseph P., and Jaiswal A.K. NAD(P)H:quinone oxidoreductase1 (NQO1) reduces the mutagenicity of DNA caused by NAD(P)H:P450 reductase activated metabolites of benzo(a)pyrene quinones. Br J Cancer 77 (1998) 709-719
11. Joseph P., Klein-Szanto A.J.P., and Jaiswal A.K. Hydroquinones cause specific frame shift mutations involving deletion of a single cytosine from the DNA sequence 5′-CCCCC-3′ and lead to cellular transformation and in vivo tumorigenesis. Br J Cancer 78 (1998) 312-320
12. Radjendirane V., Joseph P., Lee Y.H., Kimura S., Klein-Sazanto A.J.P., Gonzalez F.J., et al. Disruption of the DT-diaphorase (NQO1) in mice leads to increased menadione toxicity. J Biol Chem 273 (1998) 7382-7389
13. Long II D.J., Gaikwad A., Multani A., Pathak S., Montgomery C.A., Gonzalez F.J., et al. Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res 62 (2002) 3030-3036
14. Long II D.J., Waikel R.L., Wang X.J., Perlaky L., Roop D.R., and Jaiswal A.K. NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res 60 (2000) 5913-5915
15. Long II D.J., Waikel R.L., Wang X.J., Roop D.R., and Jaiswal A.K. NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin. J Natl Cancer Inst 93 (2001) 1166-1170
16. Ross D., Beall H., Traver R.D., Siegel D., Phillips R.M., and Gibson N.W. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. Oncol Res 6 (1994) 493-500
17. Rauth A.M., Goldberg Z., and Misra V. DT-diaphorase: possible roles in cancer chemotherapy and carcinogenesis. Oncol Res 9 (1997) 339-349
18. Workman P., and Stratford I.J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 12 (1993) 73-82
19. Begleiter A., Leith M.K., Curphey T.J., and Doherty G.P. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy. Oncol Res 9 (1997) 371-382
20. Boyer M.J. Bioreductive agents-a clinical update. Oncol Res 9 (1997) 391-395
21. Workman P. Enzyme-directed bioreductive drug development revisted. A commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes particularly DT-diaphorase. Oncol Res 6 (1994) 461-475
22. Fitzsimmons S.A., Workman P., Grever M., Paull K., Camalier R., and Lewis A.D. Reductase enzyme expression across the National Cancer Institute Tumor Cell Line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 21 (1996) 1161-1163
23. Joseph P., Xu Y., Jaiswal A.K., and Non-enzymatic. Enzymatic activation of mitomycin C: identification of a unique cytosolic activity. Int J Cancer 65 (1996) 263-271
24. Jaiswal A.K., Burnett P., Adesnik M., and McBride O.W. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry 29 (1990) 1899-1906
25. Jaiswal A.K. Human NAD(P)H:quinone oxidoreductase2: gene structure and tissue specific expression. J Biol Chem 269 (1994) 14502-14508
26. Jaiswal A.K., Bell D.W., Radjendirane V., and Testa J.R. Localization of human NQO1 gene to chromosome 16q22 and NQO2-6p25 and associated polymorphism. Pharmacogenetics 9 (1999) 413-418
27. Wu K.B., Knox R., Sun X.Z., Joseph P., Jaiswal A.K., Zhang D., et al. Catalytic properties of NAD(P)H-quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys 347 (1997) 221-228
28. Zhao Q., Yang X.L., Holtzclaw W.D., and Talalay P. Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase). Proc Natl Acad Sci USA 94 (1997) 1669-1674
29. Knox R.J., Jenkins T.C., Hobbs S.M., Chen S., Melton R.G., and Burke P.J. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res 60 (2000) 4179-4186
30. Foster C.E., Bianchet M.A., Talalay P., Zhao Q., and Amzel L.M. Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochemistry 38 (1999) 9881-9886
31. Long II D.J., Iskander K., Gaikwad A., Arin M., Roop D., Knox R., et al. Disruption of NRH:quinone oxidoreductase2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J Biol Chem 277 (2002) 46131-46139
32. Mailiet F., Ferry G., Vella F., Berger S., Coge F., Chomarat P., et al. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem Pharmacol 71 (2005) 7488
33. Iskander K., Paquet M., Brayton C., and Jaiswal A.K. Deficiency of NRH:quinone2 increases susceptibility to 7,12-dimethylbenzanthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res 64 (2004) 5925-5928
34. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Can Inst 82 (1990) 1107-1118
35. Zilfou J.T., and Smith C.D. Differential interactions of cytochalasins with P-glycoprotein. Oncology Res 7 (1995) 435-443
36. Guengerich F.P. Metabolic activation of carcinogens. Pharmac Ther 54 (1992) 17-61
37. Breimer L.H. Molecular mechanisms of oxygen radical carcinogenesis and mutagenesis: the role of DNA base damage. Mol Carcinog 3 (1990) 188-197
38. Jaiswal A.K. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Rad Biol Med 36 (2004) 1199-1207
39. Wu K., Eng E., Knox R., and Chen S. Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model. Arch Biochem Biophys 385 (2001) 203-208
40. Gustafson D.L., Beall H.D., Bolton E.M., Ross D., and Waldren C.A. Expression of human NAD(P)H:quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones. Mol Pharm 50 (1996) 728-735
41. Plumb JA, Workman P. Usually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumor cell line that lacks DT-diaphorase activity. In: Begleiter A, Leith MK, Curphey TJ, Doherty GP, editors. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy. Oncology Res 1997; 9: p. 371-82.